Free Trial
NASDAQ:MREO

Mereo BioPharma Group (MREO) Stock Price, News & Analysis

Mereo BioPharma Group logo
$3.63 +0.05 (+1.40%)
(As of 02:50 PM ET)

About Mereo BioPharma Group Stock (NASDAQ:MREO)

Key Stats

Today's Range
$3.53
$3.68
50-Day Range
$3.33
$4.62
52-Week Range
$3.17
$5.02
Volume
410,158 shs
Average Volume
798,801 shs
Market Capitalization
$509.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50
Consensus Rating
Buy

Company Overview

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Mereo BioPharma Group Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
60th Percentile Overall Score

MREO MarketRank™: 

Mereo BioPharma Group scored higher than 60% of companies evaluated by MarketBeat, and ranked 462nd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mereo BioPharma Group has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Mereo BioPharma Group has only been the subject of 2 research reports in the past 90 days.

  • Read more about Mereo BioPharma Group's stock forecast and price target.
  • Price to Book Value per Share Ratio

    Mereo BioPharma Group has a P/B Ratio of 9.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.26% of the outstanding shares of Mereo BioPharma Group have been sold short.
  • Short Interest Ratio / Days to Cover

    Mereo BioPharma Group has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in Mereo BioPharma Group has recently decreased by 11.43%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Mereo BioPharma Group does not currently pay a dividend.

  • Dividend Growth

    Mereo BioPharma Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.26% of the outstanding shares of Mereo BioPharma Group have been sold short.
  • Short Interest Ratio / Days to Cover

    Mereo BioPharma Group has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in Mereo BioPharma Group has recently decreased by 11.43%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Mereo BioPharma Group has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Mereo BioPharma Group this week, compared to 2 articles on an average week.
  • Search Interest

    Only 4 people have searched for MREO on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Mereo BioPharma Group to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mereo BioPharma Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $702,832.00 in company stock.

  • Percentage Held by Insiders

    Only 4.13% of the stock of Mereo BioPharma Group is held by insiders.

  • Percentage Held by Institutions

    62.83% of the stock of Mereo BioPharma Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Mereo BioPharma Group's insider trading history.
Receive MREO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter.

MREO Stock News Headlines

When it comes to NVDA… “acceleration cycles” are the key
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
See More Headlines

MREO Stock Analysis - Frequently Asked Questions

Mereo BioPharma Group's stock was trading at $2.31 at the beginning of the year. Since then, MREO stock has increased by 55.4% and is now trading at $3.59.
View the best growth stocks for 2024 here
.

Mereo BioPharma Group plc (NASDAQ:MREO) announced its earnings results on Thursday, September, 7th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02).

Mereo BioPharma Group (MREO) raised $49 million in an initial public offering on the week of April 23rd 2018. The company issued 2,800,000 shares at a price of $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers.

Mereo BioPharma Group's top institutional shareholders include Janus Henderson Group PLC (8.80%), Frazier Life Sciences Management L.P. (3.63%), Clearline Capital LP (2.31%) and Acuta Capital Partners LLC (0.90%). Insiders that own company stock include Denise Scots-Knight, Charles Sermon, Christine Ann Fox, John A Lewicki, Alexandra Hughes-Wilson and Deepika Pakianathan.
View institutional ownership trends
.

Shares of MREO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON), Jabil (JBL) and Builders FirstSource (BLDR).

Company Calendar

Last Earnings
9/07/2023
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MREO
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.50
High Stock Price Target
$8.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+109.5%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10 million
Book Value
$0.36 per share

Miscellaneous

Free Float
134,464,000
Market Cap
$502.13 million
Optionable
Optionable
Beta
N/A
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:MREO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners